Tildrakizumab
| 證據等級: L5 | 預測適應症: 4 個 |
目錄
Tildrakizumab: From Plaque Psoriasis to Severe Nonproliferative Diabetic Retinopathy
One-Sentence Summary
Tildrakizumab is an anti-IL-23p19 monoclonal antibody originally developed for moderate-to-severe plaque psoriasis. The TxGNN model predicts it may be effective for severe nonproliferative diabetic retinopathy, but this direction is currently supported by 0 clinical trials and 0 publications — it is a pure network-score prediction with no independent evidence base.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Moderate-to-severe plaque psoriasis (based on known drug class; no Taiwan license text available in this evidence pack) |
| Predicted New Indication | Severe nonproliferative diabetic retinopathy |
| TxGNN Prediction Score | 99.63% |
| Evidence Level | L5 |
| Taiwan Market Status | Not marketed (未上市) |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available (data gap DG002). Based on known drug-class information, tildrakizumab is a humanized IgG1/κ monoclonal antibody that selectively binds the p19 subunit of IL-23, blocking IL-23/Th17 signaling; it is used to treat moderate-to-severe plaque psoriasis, an IL-23/Th17-driven inflammatory skin disease.
Diabetic retinopathy pathology, in contrast, is primarily driven by hyperglycemia-induced microvascular injury and VEGF-mediated neovascularization. While chronic low-grade inflammation and Th17 involvement have been proposed in some diabetic vascular complications, there is no established causal or mechanistic pathway connecting IL-23 inhibition to diabetic retinopathy in the literature reviewed. This prediction therefore rests solely on the TxGNN network association score and currently lacks any independent mechanistic, preclinical, or clinical support.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Taiwan Market Information
Tildrakizumab is currently not marketed in Taiwan (0 authorizations); no license or approved-indication information is available in this evidence pack.
Safety Considerations
Please refer to the package insert for safety information (TFDA warnings, contraindications, and drug interaction data are not yet available — see data gap DG001).
Conclusion and Next Steps
Decision: Hold
Rationale: The evidence level is L5 — a model prediction with no supporting clinical trials or literature — and the drug is not currently marketed in Taiwan. Critical safety data (TFDA warnings/contraindications, DG001) and confirmed mechanism of action (DG002) are both missing, which blocks any S1 safety pre-assessment.
To proceed, the following is needed:
- TFDA package insert with warnings and contraindications (DG001 — Blocking)
- Confirmed original mechanism of action data (DG002)
- Preclinical or mechanistic studies linking IL-23/Th17 inhibition to diabetic retinopathy pathology
- Any clinical trial, case report, or observational data on tildrakizumab in diabetic microvascular/ophthalmic complications
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.